What Beckley Psytech does

Beckley Psytech is a clinical-stage biopharmaceutical company founded in 2018 in the United Kingdom to develop psychedelic-derived medicines for neurological and psychiatric disorders. Its pipeline centers on BPL-003 (mebufotenin benzoate), an intranasal 5-MeO-DMT formulation for treatment-resistant depression that received FDA Breakthrough Therapy designation in October 2025 after Phase 2b data showed 11–12 point MADRS score improvements versus 5.8 in controls; Phase 3 trials are planned for Q2 2026. A second core asset, EMP-01 (oral R-MDMA), targets social anxiety disorder and secured a U.S. patent in December 2025 with exclusivity through 2043, following Phase 2a data showing an 11.85-point placebo-adjusted LSAS reduction. Additional assets include VLS-01 (topline data expected H2 2026), ELE-101 (acquired from Eleusis Therapeutics in October 2022 and now in Phase 1), and a library of novel psychedelic compounds, plus a NIDA-funded program on non-hallucinogenic receptor agonists for opioid use disorder.

The company is pre-revenue and operates a pharmaceutical R&D business model, generating no commercial product sales and planning eventual commercialization through healthcare provider networks following FDA approval. Distribution will rely on qualified clinicians and treatment facilities administering psychedelic therapies under supervised protocols. Customer-facing activity is currently limited to clinical trial recruitment, investor relations, and patient advocacy engagement rather than traditional go-to-market motions.

In November 2025, Beckley Psytech merged with atai Life Sciences to form AtaiBeckley Inc., which subsequently redomiciled from the Netherlands to Delaware and listed on NASDAQ under ticker ATAI, with a $220.7 million cash position as of December 31, 2025 expected to fund operations into 2029. Leadership is led by CEO and co-founder Cosmo Feilding Mellen, with founder Lady Amanda Feilding, COO Andy Page, and CDO Laura Trespidi rounding out the executive team.

Name

Beckley Psytech

Legal name

AtaiBeckley Inc.

Website

https://beckleypsytech.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Beckley Psytech is a UK-based clinical-stage biopharmaceutical company developing psychedelic-derived therapies for neurological and psychiatric disorders. Now operating as AtaiBeckley (NASDAQ: ATAI), it targets treatment-resistant depression and social anxiety disorder via intranasal 5-MeO-DMT and oral R-MDMA.

Ownership category

akta.pro rank

Product category

Clinical-Stage Psychedelic Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

Keywords

• Psychedelic therapeutics
• Mental health treatments
• Clinical-stage biopharmaceutical
• 5-MeO-DMT formulations
• R-MDMA therapeutics

Headquarters

HQ city

Beckley

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Expected to generate revenue through commercialization of psychedelic-derived therapies for mental health conditions following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Beckley Psytech is a clinical-stage biopharmaceutical company developing psychedelic-derived medicines for neurological and psychiatric disorders. Its core pipeline includes BPL-003 (intranasal 5-MeO-DMT / mebufotenin benzoate) for treatment-resistant depression, EMP-01 (oral R-MDMA) for social anxiety disorder, and additional novel psychedelic compounds acquired from Eleusis Therapeutics. Following the November 2025 merger with atai Life Sciences, the combined entity AtaiBeckley Inc. is advancing these candidates through FDA clinical trial phases toward commercialization.

Product overview

Beckley Psytech (now part of AtaiBeckley following the November 2025 merger with atai Life Sciences) is a clinical-stage biopharmaceutical company developing psychedelic-based medicines for mental health conditions. The product portfolio centers on BPL-003, an intranasal 5-MeO-DMT treatment for treatment-resistant depression in Phase 3 development with FDA Breakthrough Therapy designation, and EMP-01, an oral R-MDMA formulation for social anxiety disorder in Phase 2a. The company also acquired ELE-101 and a library of novel psychedelics from Eleusis Therapeutics. Pipeline assets target conditions including treatment-resistant depression, social anxiety disorder, and opioid use disorder.

Differentiator

Problem solved

Functional benefit

Products and services

• BPL-003 (Mebufotenin Benzoate) Intranasal 5-MeO-DMT psychedelic therapy for treatment-resistant depression (TRD). Phase 2b demonstrated statistically significant reductions in MADRS scores with 11-12 point improvements versus 5.8 in the control group; Phase 3 trials planned for Q2 2026. Holds FDA Breakthrough Therapy designation.
• EMP-01 (Oral R-MDMA) Oral R-MDMA formulation for social anxiety disorder. Phase 2a trial showed clinically meaningful 11.85-point placebo-adjusted reduction on the LSAS scale. U.S. patent granted December 2025 with exclusivity through 2043.
• VLS-01 Psychedelic therapy for mental health conditions. Topline data expected in H2 2026.
• ELE-101 Next-generation psychedelic formulation acquired from Eleusis Therapeutics, currently in Phase 1 clinical trials.

Quantifiable outcome

• Phase IIb BPL-003 showed 11-12 point MADRS score improvements versus 5.8 in control group for treatment-resistant depression
• +2 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered flagship, core and minor.

• Atai Life SciencesflagshipStrategic or Co-development Partner · 5 November 2025Strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited completed on November 5, 2025, forming AtaiBeckley Inc., a global leader in transformative mental health therapies. The merged company focuses on psychedelic medicines for mental illnesses with a pipeline including BPL-003 for treatment-resistant depression.
• PsyPAN (Psychedelic Participant Advocacy Network)coreStrategic or Co-development Partner · 1 January 2025Multi-year collaboration on participant-informed psychedelic clinical research including qualitative workshops, published white paper titled 'The Participants in Their Own Words,' and 12-month independent peer-support pilot program for UK participants in 2025. Expanded to include international patient advocacy organizations and academic collaborators.
• King's College LondonminorStrategic or Co-development PartnerAcademic collaborator in the expanded PsyPAN partnership for participant-informed psychedelic clinical research.
• University of ExeterminorStrategic or Co-development PartnerAcademic collaborator in the expanded PsyPAN partnership for participant-informed psychedelic clinical research.
• NIDA (National Institute on Drug Abuse)coreStrategic or Co-development PartnerGrant awarded for developing non-hallucinogenic receptor agonists for opioid use disorder, supporting research into novel therapeutic approaches.
• Eleusis Therapeutics LimitedcoreStrategic or Co-development PartnerAcquired in October 2022, gaining full rights to Eleusis' assets including ELE-101 (next-generation psychedelic formulation for Phase 1 trials) and a library of novel psychedelics. Eleusis' research team was integrated into Beckley Psytech.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Compass Pathways: Compass Pathways is developing COMP360 psilocybin therapy for treatment-resistant depression, the same primary indication as BPL-003. It is the most advanced publicly-listed pure-play in psychedelic TRD therapeutics and serves as the benchmark direct competitor.
• GH Research: GH Research is developing mebufotenin (5-MeO-DMT) for treatment-resistant depression using the same active pharmaceutical ingredient as Beckley Psytech's BPL-003. This makes it the closest mechanism-overlap competitor with potential to commoditize the 5-MeO-DMT category.
• MindMed: MindMed is developing psychedelic-inspired medicines including LSD-based therapies for anxiety disorders and MDMA-related programs. Directly comparable as a clinical-stage psychedelic therapeutics company pursuing similar psychiatric indications.
• Cybin: Cybin is developing psilocybin-based therapeutics for depression and anxiety disorders, including proprietary deuterated psilocybin analogs. Operates in the same clinical-stage psychedelic drug development space targeting similar mental health indications.
• Lykos Therapeutics: Lykos Therapeutics (formerly MAPS Public Benefit Corporation) is developing MDMA-assisted therapy for PTSD and other mental health conditions. Direct peer in psychedelic-assisted psychotherapy with similar regulatory and commercialization challenges.

Emerging players

• Delix Therapeutics: Delix Therapeutics is developing non-hallucinogenic neuroplastogens for depression, anxiety, and other CNS disorders. Adjacent approach to psychedelic therapeutics but targets similar mental health indications with potentially easier administration.
• Filament Health: Filament Health is developing botanical psilocybin drug candidates for mental health conditions. Operates as a smaller, earlier-stage player in the psychedelic therapeutics category with overlapping regulatory pathway.
• Silo Wellness: Silo Wellness is developing psilocybin-based treatments and operates psychedelic wellness retreats. A smaller emerging player with partial overlap on psychedelic-based mental health therapeutics.

Broad incumbents

• atai Life Sciences: Atai Life Sciences merged with Beckley Psytech to form AtaiBeckley in November 2025. Pre-merger, atai operated as a broader psychedelic mental health platform with multiple programs (psilocybin, DMT, MDMA) across depression, anxiety, and substance use disorders.

Others

• Eleusis Therapeutics: Eleusis Therapeutics was acquired by Beckley Psytech in October 2022, providing ELE-101 and a library of novel psychedelics. Now operates as a wholly-owned subsidiary, contributing to AtaiBeckley's pipeline rather than as an independent peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/beckley-psytech

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beckley Psytech